Stay updated with breaking news from Chemo Io. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.
Experts address the impact of platinum shortages, 4-cycle platinum chemotherapy, and available treatments beyond platinum chemotherapy.
Experts deliberate on the optimal timing of chemoimmunotherapy and if it should be before or after surgery.
Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, review the frontline treatment armamentarium available to patients with follicular lymphoma.